Sarepta Therapeutics - Just Wow

This Sarepta news is simply mind blowing. Just when you thought it was all clear with a “black box” warning for its gene therapy product Elevidys and a massive restructuring, everything hits the fan. A third patient death was just revealed, and now the FDA is instructing the company to halt shipment of Elividys and they are refusing the order. I do not see how the company gets out of this one.

I have been tempted many times to dabble into an option position in Sarepta with its high premiums, but news like this will simply destroy you if you are on the wrong side. It seems like black swan events are an everyday day occurence with this company.